Inventor(s)
`
`MANTYLA EINAR [IS]; ORVAR BJORN LARUS [IS]; BJIARNASON
`JON BRAGI [IS]; BALMER YVES [CH] =(MANTYLA EINAR
`- BALMER
`,; BJARNASON JON BRAGI
`ORVAR BJORN LARUS
`YVES)
`
`Applicant(s)
`
`ORF LIFTAEKNI HF [IS] = (ORF LIFTAEKNI HF)
`
`AGIK31/728; AGIK38/18; AGIK8/G4; COFK14/485
`
`
`5
`AGIK34/728(
`AS1K38/168 ¢
`EP,US
`US
`AR
`EP,
` 5
`.
`ASLKISM808 {
`}
`ASIKSSI18 ¢
`EP, US
`US
`EP, KR
`GIK38/1866 (
`AG1K38/1841 (EP,US)
`EP, US
` 5
`
`s)
`}
`AGIK47/02 {
`AG61K38/2006 (EP,
`EP, US
`
`
`3
`by
`TS
`ASIKBIG4 {
`ASIK47/10 f
`EP, KR
`EP, US
`
`EP, US%
`}
`ASIK9I0014 {
`ASIKBITS5 (
`P, US
`5
`3
`AS1K9/06 (EP, US
`}
`AGLOLIIOO?
`EP, US
`3
`C12N15/8257 (EP,US)
`]
`COTK1448S €
`EP KR
`us
`more
`
`‘}
`
`‘
`
` }
`3
`
`5 E
`
`} A
`
` a
`
`}}u
`
`Classification
`
`=In
`iona
`ternat
`- cooperative
`
`Application
`number
`
`1orl
`ity
`Pri
`number(s)
`
`KR20127020435 20110106
`
`Global Dossier
`
`is 20700008877 201007106
`
`Also
`published as
`
`ALUPCOT 204391 (Al) BREI2O12016575 (A2) CA2Z7 85637 (Al)
`CN102811704 (Al EP2521532 (A2). more
`
`os
`tee
`
`ed4ae
`
`Pts,
`
`es
`
`ca
`wb,
`
`cnet!
`
`
`
`

`

`BSIFSG 10-2012-0115535
`
`
`
`CO (19) Up ShelSES) (ER) (11) 78S=10-2012-0115535
`
`(43) Sz} 20124109182)
`(71) &ael
`Qo] BZA oo]zjay=
`
`ofo] Set= ofoo] 4-203 Stabe wee
`= 3
`(72) Wry sp
`Welz} aos
`
`8 (12) SASS ERA)
`(51) Sas 424 (Int. Cl.)
`AGIK 38/18 (2006.01) AGIK 31/728 (2006.01)
`AGIK 8/64 (2006.01)
`CO7K 14/485 (2006.01)
`(21) 29Hns
`10-2012-7020435
`(22) SMa)
`2011.4014062
`ABT SA BR
`
`oeJ@8e ofel2-104 Woaaya, 2u]
`(85) WAtalea} 20124082029
`HY?) 18
`(86) aa] 42181 PCT/1S2011/050001
`2Sy= He BFA
`(87) =a) S71HS
`WO 2011/083500
`
`
`sal S7aU sz=.2011407411498) o}o] SAE ofojo] 7-200 SuEPs SEES
`(30) -?-Ad Fae
`“
`8871 2010019062]
`(AY Ae)
`(74) Hele)
`Bassa gel
`
`ofo] 2M = (1S)
`
`ala] ASS 4: S 35 Sh
`
`(54) Wee]
`
`
`
`«|$0,
`
`
`Bal BB Aegoya ease ASH Vs clas Aeste a
`
`
`at A), Bs BS ofA] ARS sty] HS, As Mss Bs GaAs AS $See, SE Baas
`
`JSSBIT 89 4, BE FHS EE 2H Sel SAds JBSHe Hada VWs ets] =QHS
`& EPS, U2 2B Berye2 ZY =(cosmetic and dermatologic composition)] we we|]t}. Sessa],
`
`Bal We Sar 4S Ha Aes + Yoo tess, Ur} tas ADA sts Alea}. seas «
`
`—T
`AES A=-A]4(plant-produced) Wt ele, B PPEBAS BHSr}. Crgssl Vt Mss Boke, W4-
`
`He/BPse AYES MASS Ed AGE 2 aye) aga] B89 see] HHS 44 Ger. Sd, =
`1
`Te
`— H-—
`Yo] 2YBS SE EE velo} AM 7Wa AAGoese] rela = Ve Sas Be Ady wal
`(transmissible agent)S M@s}4) S=Ec}.
`gf 38 XS - 6
`
`aa
`
`
`
`

`

`= Hz)
`of] S-101 Bo) ope a ADAH
`
`SIS 10-2012-0115535
`
`wey Opa
`AMA ABH 1950 A) Fo]
`
`a] A} axa 9
`
`

`

`BSIFSG 10-2012-0115535
`
`
`
`ATH1
`
`a]geEBA GZ Su} ol4ts]) GAws ASSHeE Gas Ws ola, @ au ol4te] Salts oe Pg/e ty ys
`
`Aoeg Bea7-oa Bays SSE, WE He /BPsrye 242(skin care/dermatologic composition).
`
`4A, 84 at GYAe aselyle BSA] ZAlE (excipient
`
`formula)S? ZVHs=e Al WS
`
`
`off of 7)\#O eB
`CF 0.01 % WA cof 2 GS] SES ASRS aw £2
`ATY 1 FE 2 MIA, A] IAHEAS
`Wy he] /B se AWE.
`
`APY 4
`
`
`
`Bee TuaSas Bad Mis, a]V8 teWS 8SSol RYE CAda AS Fe
`2]
`= Abo ASS e 4
`
`ATTY 5
`
`
`Ape 4] VA, 27) 24 alse ay) 2444 AS FSH So S GAA Hee] SF 0.0001% Yr]
`70% 292) Hoe Sse Al Be Be /VSse 298.
`
`oF
`
`ATA 6
`
`Apa 4 He 5VHA, a7) AS Sees 2y) Bs UMA} B3kenrich NES Aas Al WA Bel/
`BBs AYE,
`
`ATA 7
`
`
`ays} 4 HE 5] PUA, Ae WE, Se, Be, Aces FAA(cracked skin), BA, W BA(skin
`redness), @H #4, AN, BPS SF FU ol4oeHey Ale WE Ate] JSS Ma Ae Aol Wy
`
`ALY 9
`
`
`
`QED so] MoM, a) GYs ohegsp AL sy] PUSH 7S WS BMP Bel MH Bes ps
`292: 10 Wl2] 90 & M912) SEAS. 0,1 aM viA) 200 mM WHS] Sst ZH,
`6 UIA) 92) pI He) Meal
`BW Sse t(¢g.s2] Aas.
`
`Ay 10
`
`
`AF 8 HE Go] QA, 7A] BoyPeA SE BES Bt] SE All WH Hel/Beaye
`AMS.
`
`APY 1
`
`AeY 1 U7] 10S FS Me Bo] MIA, BAAS ASEUS Has BI dds 24 oF BPH Vel
`Be wel/s RSLS eA
`
`

`

`SISA 10-2012-0115535
`
`Ares 12
`
`49,
`APY ie] oq, A) 2 lye] As dae Aas AG FSES] =
`WE He /BPsS B=
`
`OF
`He) ABom SAL Aol
`
`oi
`
`APY 13
`
`S
`A= AZ) BAAD AS FSE92] SG] BHA seo] of
`ALY lo] VHA, a) 2S clas] BA aa
`0.0001% HA] CF 70% Be]e] oboe BASE Aol WT
`
`ATA 14
`
`“~d7] St o/s] Bet als HE A] 2E olds] Ast aszhe Ss
`ats} 1 U4] 13 Se UL SF So] glory,
`AAS ASEEE Besa,
`oF
`70% U4) CF 99.9% HHS] Se Pen] dale Al HS wel /BSoe 2
`Ie,
`
`ATA 15
`
`ast 1 uz] 14 S FL SF So] gor, srt ole] AS-i aale Bs? els} oF] ASFA Vs al
`
`AS 2 Vshe G448 AS $e A74Ae AM By we/Byets S29.
`
`gq teeee Ase Aol YS Ae/Be 2YE: Hy A 9l4}Epidermal Growth Factor,
`
` Ape 1 uz) 15 S FE SB Soy orl, wt) Sr} ots] es“4 ols, Hee 77) 2S ol4te] A else sf
`
`EGF), @zt 7x] 4%} el4}(Vascular Epithelial Growth Factor, VEGF), PDGF-AA, PDGF-BB, % PDGF-Rb= 3 ¢
`
`
`e G2ARW-Fa 24 ¢14+(Platelet-Derived Growth Factor, PDG"), FGr-a, & FGr-b, Far-4 2 rar-6g =
`SAIS A424) 2l4+(Fibroblast Growth Factor, FGF), TGF Se}-1, TGF ae}-2, TGF ae}38 SAH4t,
`aAaASst 24belz}(Transforming Growth Factor)-MlEKTGr-b), SAAS AWA z--YGy(TGF-a), Hele =B@Xo] ol
`w(Erythropoietin, Epo), ¢la&@--AF 4 214-1 (Insulin-Like Growth Factor-I,
`IGF-I),
`¢l@&@—--A} 714
`s14}-ITCIGF-I1),
`IL-1 2s} ® IL-1 BERS Sebel ele 21-1Unterleukin-1,
`IL-1),
`:hA#2Z-2CIL-2),
`¢1
`EV Z1-4(1L-4), QLE}PZI-SCIL-5), LEP 21-6 (IL-6), GlE4PZI-7(1L-7),
`lE}S+Z1-8(1L-8), ele] 3+71-10CIL-
`10),
`SLA Z1-13C1L-13), 9) -Z1-15CIL-15), le} xZ1-18(IL-18), Slay z1-20CIL-20), Sef BAR G14
`S}CTNF(Tumor Necrosis Factor)-a), @°F BAF e14--SECINF-b),
`912) 4] 2-2 e}Cinterferon-gamma,
`INF-g),
`see eb ARS 91 (Granulocyte Colony Stimulating Factor, G-CSF), *+H-- AAS et 2b ols}
`(Granulocyte Macrophage Colony stimulating factor, GM-CSF), GAAAIM #2 4-4 914+(Macrophage Colony
`stimulating factor, M-CSF), ®lgt 2%} 914+ (Placenta Growth Factor, PLGF), #14 4% 914i(Nerve Growth
`Factor, NGF), Z}4A)% 44} SlA4bCKGF), BS Ge} 41 (BMP(Bone morphogenesis Protein)-4), Zt] 34 el
`Al(lepatocyte Growth Factor,
`IGF), W8l(Leptin), %7l(Noggin), @ ELE) Ble}(Thymosin beta) 4.
`
`gh
`uty@
`
`APY 17
`
`AFD 19
`
`7rd 4716 Fa @ Bol MIA, BW) BSAAM JS FSB ISA (dchydrin) B/E GRR
`Ee et Sd GMAS SMHS Bel HE wel/sVape ays,
`
`ATS 20
`
`ApS 1 Zz) 19 S Ae tt Sel glolAl,
`
`
`-g7]) YS AH, 2A, A, Baled, A, PaACincture),
`
`

`

`BSIFSG 10-2012-0115535
`
`
`glo) 2E (paste), AZ, HHsalve), #E, 4A HE WHA (semiliquid) AA, AWBserum), W4l, AYNS
`AlAl(liposomal preparation), #8, Seal, aexs See W/o S©= O/W ADA, SrbE(pomade) 2 WF
`
`
`As}4] 24 (skin softener cream), ¥]°]4 VACfacial pack), =}AKZ] 34, 2Gof AB HE 2 yaeae
`
`BRE ABS alae ael Wh tel/BAypss 242
`
`ATA 21
`
`aU} ol4ts] Baas ASSBE Hae Bt eds 2 esarles Stee GIA as 242, 2 SES
`2] 4rSe Boe, YH BA/BS29=
`
`Ava 22
`
`
`ATS 215 VA, A34es, S342e 4 S5e4eceey A4a FSU Vs Al WH Be/ys
`Tee BAS
`
`ATA 23
`
`apa 21 He 22] SoA, ASPHAAS VU] SSH Ael BA Bel/Bpss 2ge.
`
`APY 24
`
`Apa} 2 EE Bel MA, GAA JSewe Hay Ys ala, B10 FH ul 90 Sew WS] Sela
`
`=, 0,1 mM 4) 200 mM BY) As} Be, GH @ SVs tg. AS AUS BYE Gud og
`3} 2a)22 SPAe) TY wel/syope RAE.
`
`APY 25
`
`BEY 21 7) 24 S ot. BM Bo] MOA, S71) BIAEA TE MEMS SMe] SE vel WHE gel
`az
`[3238
`
`BPR 26
`
`ae PAG Tesyee AAs sh} jel
`
`|r
`SF Soy Vor, Ay] Wt MAE
`ASS 17 UA) 25 SF Ot.
`AQ BA ze]/B a} e AME: SEX AA QlACEGF), &
`*$u] 79% Q1AbCVEGF), PDGF-AA, PDGF-BB,
`
`PDGF-RbS MBG AA
`AlZzR el z}(PDGF), FGF-a, @ FGF-b, FGF-4 @ FGF-62 %@3 AfRBAE AA
`QI4-(FGF), TGF AlE}-1, TGF
`PE}-2, TGF WJE}-3S Vee GAs Bsels-ver(iGr-b), Saas Bells
`ety} (TGF-a), Wz] ESSME (Epo), eee-sae 34 SlLALKICIGF-1), cle e--4} 49%} ol AF IICIGF-II),
`IL-1 23} SB IL-1 WES MSHS VEZI-1CL-1), Vea Z-2CIL-2), eyPzl-4C1L-4), ele) 4°Z1-5(1L-5),
`4HTn
`lE}-FZI-7(IL-7), QE =BzZI-8C1L-®. AR10CL10), EF71-13(1L-13), ee ezZl-
`Q1e|==ZI-6CIL-6),
`~~
`15(IL-15), @lE}ZI-18CIL-18), Qezl-20(1L-20), SM FAL Q2}-SH-CTINF-a), SM BAL @14]-H] EL CTNF-
`b), Ge aS-ZuUECINE-g), 3}Aa ARS olzGCSP), Hey GAAS BS zh] elzbGM-CSF), YAyAe
`
` a
`
`Ae 2} SIZEQECSF), EqRE4} O1Z(PLGF), ALS 794 OIZECNGF), ZS AM BA OZUKGF), SS Ua
`(BMP-4), ZrA]S2 4a% ClACHGF), We, +zZ1, @ EwAl we} 4.
`
`BPE 27
`
`oka] SA] APS SEZ] SS, H-AS +414] 7] Ql(mon-plant genetic origin)2| AS-aAz oo] AS el zb(Cplant-
`produced heterologous growth factor).
`
`AP28
`
`az WD, SA, WEA, BeTy, Ua, SY AT, GA, WE D4, RPS S a yong a
`Ag BR AMS] ARR AIA ASS) Met, VI-AS Has ale] AS-aAz oS Ya alt
`
`APY 27 HE Wel MUA), 7S Ted Peete Age zlel AS-de oS BQ Us:
`x}
`(EGF), Bat ee] at 21%}
`(VEGF),
`PDGF-AA,
`PDGF-BB, % PDGF-RbS “BG BaAW-Hal Ag ly
`(PDGF), FGF-a,
`31 FGP-b, FGF-4 3 PGF-6-&Het YEAS 23% O1x}(RGF), TGF WE-1, TGF YE}-2, TGF
`
`-45-
`
`

`

`HEL3S SSS SAAS Bsels-Her(lcr-b), SAAS BVselz-YUs(TGF-a), WAIEBXS]YACEpo), 2
`eas AA SIAR ICIGF-1), Sh -+-AR 424} O1AFIICIGF-II),
`IL-1 Gs} @ IL-1 WES SSS 17
`
`SIS 10-2012-0115535
`
`E] = 71-8(1L-8), QE} ZI-10(1L-10), ele FZ1-13C1L-13), gle) ZI-15C1L-15), 21e)FZ1-18(1L-18), daz
`
`-1(IL-1), 91) 4%1-2CIL-_ SIEAZI-ACIL-4), Q1EARI-5CIL-5), S1EFZI-6CIL-6), 1B 44Z1-7(IL-7), 2
`Z1-20(IL-20), 2% aQIA}-SSECTNF-a), GU SA G14}HyERCINF-b), 91]FI-4beCINF-g), a ae
`
`A Q1AKG-CSF), SRST! OAV EOP x ALAEGALCSP), GAAS Qe AS elxbAeCSP), Blk YAR elt
`(PLGF), AQ 8 IAG), 4A QA MAKGF), BBY BMABMP-4), Wa Bt MACHGE),
`Wa, zl, 2Al wep 4,
`
`ATF} 30
`
`Avy 27 HE 280] VA, Hy Ast elstel alel AS-qMH ol S BA elt.
`
`APY 31
`
`sase GAA AS 442522
`
`He ne
`oeHS
`
`of,toy
`IRE, shy olde] BBA BY splzPe] asa ast dae
`»& ok
`Poe GAS MSE, WAS A Copical product) S ALsE
`> 2M) A 2l4tChGF), Aa a
`
`ot
`2} SL X-(VEGF), PDGF-AA, PDGF-BB, G PDGF-RbS 43} QA3---a 4d4F Ol AH(PDGF), FGF-a,
` FGF-b, FGF-
`4 4) FGF-6- S36) 41-f-A]3 494) Ol44(FGF), TGF AE}-1, TGF HI eh TGF WJE}-3S 4ES FAAS as
`ws
`SAEuEK(TGF-b),
`@& Aas Aysbelz}-2S(1GF-a), oe] =#Fo} Epo), Meat ast MAI ICIGF-1),
`leee]—-f-A} AP4}
`OL X}-IICIGF-II),
`IL-1 Gs} @ IL-1 WES 2S AMS SZ1-1CL-1), MH 71-2C1L-2),
`SE) FzZ1-4(1L-4), SE) ZI-5CIL-5), 1 E] 21-6(1L-6),
`Sl E-#ZI-7C1L-7),
`Sl E)#2I-8(1L-8), ele) zZI-
`10CIL-10), Qle+41-18C1L-13), Qe 441-15C1L-15), gle 2-18CIL-18), Qle}=41-20(1L-20), @ek HAF 9h
`AL-QESECTNF-a), SC SAL OLAvuERCTINE-b), GLE) SIS-ZeECINF-g), =H Bet 2S elAKG-CSF), 24°
`HANS 4S 2S SIAECGM-CSF), CHAISESP AES RL *EGMECSF), BRE 7dQIAECPLGF), 41-3 do) 4}
`(NGF), ZFS 72% SLARCKGF), @SAd Ge acByp-4), Zh 44 OAHHGF), Be, 271, 2 BBA et
`4.
`
`Ae} 32
`
`Ae B10] BLA, zy) Su} ol4be] BS a= BAe, Sade 2 SS BPAE All wy.
`
`ATE 33
`
`
`QPy 31 B= 32VA, Ay] SAAS FEES He] Sz pee Ael HH.
`
`BTA 34
`
`rr
`
`ayest a 33 So @ Yo] Qo, a7] SAMs AZ FSERHE BQ] AD Ide Gee a
`
`ASC}
`
`ERSHS lel Ug.
`
`AA 35
`
`
`APY 34 VIA, A] eA Bae JL DH AS TETGHS gsdas BME wel
`
`uaH-o.
`
`
`
`
`
`[9001]
`
`ou
`tH Wyo Zea oOes ) GEL xe]
`
`ne
`
`oO
`ow
`ase Pd lz BW aAsoyeAels
`IY. we] AES aRYo] gee
`Q°
`AS °]Stheterologous) Ws e144 ZB UWS
`
`a
`
`[0002]
`
`
`
`
`wu), 2 SHY PL yee SS Pass ela) 7S atelep. ala
`
`

`

`SIS 10-2012-0115535
`
`
`Ye Ask wey ops, yee PeisBab} ype] Mopadch. lela w
`3 3
`
`ase] +
`-
`a BBS] He Brel Esl, AB BQ ast KA19] FA] PAs eps. Aa KGS] vs} Aass]
`+
`t& 84 Fee SaA Be] AAS Bary. Het, AB’ Sto wet, AAA, 7lICfreckle), WA
`aa, HE SR WP BW S7peteh
`
`
`turnover rate)2] A@- S24 ZA Ade] AAs S454BAR, ey AS
`SEX) wtA)(epidermal
`(senile xcrosis), 2}t}é 4A 2S B ABH (finc wrinkc)S BBS}. = HHAOCR Ol4A AAANX BS
`(aberrant keratinocyte differentiation)a4] 7]/e1S - ert.
`
`24 8 zAS|Ala} 2 2484 22S] Bs] 2S TSAA + Vt. BS Y Are S OB zee BZ, B
`He He ASWAs Ge SH AAs ae; So] GAA, att 2 FF 24] +relsto], BAS] HBS #2
`
`Hee}. clo ue}, FH, AVR He 7] WA, BR Gao] Fa, aa Qa, 2 ys] ax BP eps
`ol oper EPPS] ASE} EDS AEH.
`
`| BPRS] AA sagging) B UBel 2] eh
`
`SE Bale ashy SshAl717) aa res BB ZA ES AMARch ae Ss] Sq Bea 5
`
`Oo] SAL Sepa GAs Sep)
`2468382. Sep] Bo] Sah VPS] SSS ASE YRS MAMMA}.
`Aa SaaS Lease Sepa popals] Bago] ws} we} Aspsjo], 7}al Sepdle] Sy; Be yy see] S
`7} BAD H Yep aA) ater},
`
`ye. Z2Sk(Skin condition):
`
`
`
`AAS Wo] 4Ay aay og BA BS (spot)A Vea Bscaly patch) # WS Bese Ase WH ase
`
`olth. AAA Bpsoriotic patch)h= BAA) AXSS] Ass 44 ASCs2g AX Be 2 AZ
`
`wa Feo] Ms] S| sk scp WA AAS] BHolch. AAA Us] era AJZSE ASE9 USS ZAWSE
`JS ASA FHSS AVS Aol 244 ach. AAe Ges} ge 2 tao] sje] FS + We
`
`A‘7|-=2SHA (self-incompatibility)S BAe —= We AA Bee] gee Sela gry.
`
`v4) (eczema):
`
`ae Eye] WEAR, BE BH$e] @ Solty. 29 FA(eczema)\ = OSM 24] WY ASM(persistent skin
`condition] S4Hs-7] ASecp.Set B24, WP PS), 7a 2 as, 7 AA (crusting), '
`
`
`
`W @Al(flaking), @#¥% GJ (blistering), eh(cracking) ee 87) areozing) He 2a Gs =
`
`au oats Fae YR As 2 Aes GAS FP}. HEAL SS ABQ AAMzZOL] Ba Aes
`
`ce. U4 oko} Cthinning)*} 22 SSesoles? AYA AA Weel, 2qBzlee Fe4le] AWA
`(episode) S AlOS+7] AAG HSA] 4-25) °]°F Sr}
`
`
`
`AY Use ASo] SA 2 BSS 2AEH 44 Fes Sasa, aq 2s | Ey B 71AS (basal
`lamina)2) aPae] Bosc}, o Se Ales] FAS Aa Feaa, Bey, was] fe SUS F244 +
`al, FAAS23}, ASEAN42442 A4sya, AZ @ ANS 4RSe] wa] B@ AASFES = Ve.
`
`Ito S(2009)2 7JZ WSS(AsM) AeA, MMP(Matrix metalloproteinase) @ TIMP(tissue inhibitor of
`metalloproteinase)2] Wee] #epal ata] Bo] AMES] OS BAS, ep FIZ ByVal 7AS +
`
`ans AS BLAS}. PDGF= mRNA EB Et Al <=<20] 4] MMP-1(Matrix Metalloprotease-1)2] BAS wa-A) zt
`
`LAS}, TGF-HES} APSh= A, PDGME MMP-39] 24 AS SAS HY Sc}. TIMP-12 TGr-HNe} B
`
`{0603}
`
`[0004]
`
`[0G0S]
`
`[0606]
`
`0007}
`
`[008]
`
`0009}
`
`0011]
`
`[0012]
`
`[0013]
`
`foe144
`
`

`

`fO015]
`
`[0G16]
`
`fOG18]
`
`[00194
`
`[0620]
`
`[0021]
`
`{0022}
`
`10023}
`
`{0024}
`
`SIFSA 10-2012-0115535
`
`PDGFSe PPA OS PYRAS| Yr}.
`
`Nakatani $(2009)2 8|¢h# (hyaluronan)3]/4¢ ey aje1-q MMP-12) Wa BY wed So] Vee vy
`
`acs AS DASE}. SRS Se] W(HAoligo)t: mRNA B GMA Fe Ve] MMP-1 WAS aAxAspy S
`7A] Bo, TIMP-1 BS TIMP-2 mRNAS|] BSH] Wet ate SHIs7) Ker}. HAoligow HPDL A)Xe]4) MMP-1
`
`Das -Sa, p38MAPK7} HAoligocl] 2a} 4-=Sl MMP-12 Aa AS AWA Sat FHS F-UAce A
`o] AJARS| LEP,
`
`o ® Nakatani2] AdeSE BAe Badd ASB’ As geo] 838s}, Se
`
`asStel az] ae] Wee23} Aes As Boo ite] wal(turnover)o] SS WA + Ww
`
`21
`
`At (4h U}ors WE Ag Bo wyyp Sto] Gea +84 SS 74 UD, AM THANSH344
`= Sse we alse] ase] es] ete SA + Ve Aee age. Vs asthe AK AA
`
`2S4qe 28 + Vat Ae) 4] HAS] AA BAolrp
`
`EY] AG 24 HGH= VMN 2 Sms7a oss Ay] AMS] EAS SAG}. BT] AT Whe
`
`AJ, Bs], ad @ Eto] 4wl44 SA) SSC} (Carpenter, G. and Cohen, S.,
`
`"Epidermal Growth Factor,"
`
`Ann. Rev. Biochem., 48, 192-216 (1979)). HY) 2 elke 53749] Oecd 4B TAS UY SaWeeS
`o]a 6,200 Bee) Basse g2eck (Campion, S. R.
`and Niyogi, S. K., “Interaction of epidermal growth
`factor with its receptor"). 196246], Cohen2 44] FA MFA s] B ofl We ACgland)oBye] EGS
`He] wc}. 19724 ¢], Savage2t Taylor= ERP: EGFS|) Gx HS 2 FGFS] VAS Zl so Se sel avqe] 24+
`Wee age] 74S Solar.
`
`EGF 363] AM, WS] AM OS SaAMS] SAL, A eM AM} Ae ROMS] HY AMS] OS RSA
`
`& Be) S2ls+7) Weed, Fe ese] da SAt 89S Ge Aes Aer. ga else 44 A214
`(tissue integrity)2] +4] 3 AlM-d-AMt 2S(cell to cell communicationIA BA4 AX#S Sysa,
`oes),3] BAS] BSS He Mu) 2S FES -aMstrt.
`
`618,54433= EGF, TGF-a @ FGFS Bee, We
`2H aq AaSB BAA] SBA, SHS Al
`AMES MAH,
`SHE ASHALAISL, HPS] YRS MAA A VS
`
`D,
`
`TSS 3] 716,589, 5405 EGF7} Uy
`
`2] He Asaay4eoe 2aUt= AS iw]
`
`,
`ToA, ASHE WSS SHS A457] SAADZ, BM, WHS
`a
`
`qHaAANZ 2 s7BAleel Ae SF}
`PDGFs+} 234 el4te 24 UA Sel AA BAMA HAD, SST,
`Al
`SO}el = a (chemo-attractant)= +8}. eo]
`ASSES 2A SSA Frelejors] APA Bl Abe BA
`
`(necrotic debris)2] AlZoA] 623 FSS paler. 2433 GAASZE Hel S222 SAS BA
`
`ZS2PrAZ WAS PSH Sese 87 US Cyst. GVAIZS AEA WSS AZ] WE
`
`
`B28 AGES asoTGF, BR AVSss SAGVES Byer}. 4FAAe7} Sta Bales
`(wound bedIS AYLMA 2D ShCepithelization)7} 1Bac+. webs], 444 9127} Al wha
`
`Alee= Ae] SHS Qa, Avs GCSGEse Sud Ate] 41Bc14 FES + Boe aeLEPAC},
`
`EGFE 47SAS 2 44S] SAS Saletcy.
`
` FGF ES] AMO] At SA SS 7144, Se BSA WS Ay 278 IGASe ASS Bets.
`KGF-2% 4] 4) Ss] 7ISAl7]a, Sel, 212] BS (closing)& 7s Zc}.
`
`Se #4e)Uy adyoehy das ad ate ate 24 2 AS? Wal(Ctransmissible agent), 4
`, Sue, Jeb F-434) (co-purifying) 4 c14-S Bes, ojo] Bay, SE
`AGS Her. QAAZl=e AA AAA BS dela ast esate] SAS HH] A
`
`
`
`
`
`
`| 74 ahs BS DPA Ze Aes SA sz ae Uses 1(earryover)
`¥
` Ab PS was aewaist, oles ASE
`2S2] “aa 34] (bi oactivity) 2; Ja] Bast, oye
`
`ee 7} AMA ASRS Bt Clap] SAMPstc}. eleopoyA ASSaA Ho
`
`J
`
`
`Js
`
`YoAy -
`
`JalCinclusion body) Uo] BAA ZU. Gas Bqeypee AME AAAS AAMBA92e FEapy] Sa
`a
`
`ar SHABouse BAe se. ws, Helos BAAS eases4 + BD, ce, 44 4
`
`o], GAS’ EL esp] spar, Evjopaa] }gt Beja) wy wgdsp) see Aes Yea as. aa”
`
`
`
`

`

`
`
`
`
`
`
`a3bPRSooocaWoeoebereapligiaitt:omeegies$F8yeeepeeleiteol~eeemEetsaBeCaeEKB)ye©mn5setsBe28HppaneerSEECer=Ke®bg~*sues©5oexoasmRegeneee&eeoyohTeEechabOke*°wiigspoeSueyaaouFPy"lest7weTepreasaweSm>SagemafeeLigzeis=.KXgghFire9ttcteeaiedlamoPbegetery«&apweeBoe2oyyoohzKg®Hoag8oh2kEee
`
`
`
`
`
`olxoBOapeeeaeee"beaZhugnxXoeaaTohreceLNW4g®a=WoneeTeT
`
`==vegeiiycgiste:eexte‘eweReeeTagess
`
`zoBe"PPuneEiderdesateKMeSaFoyoyspigeheempxaHEH=rewatpebevaqbtee!
`
`
`HoriUETELEGERHBSOeol¥weobbe?Eraye=K°0ByNamefooO}=NUXOjotnmooNm|
`
`aanio!IHo9BPozeaMxTHomo9oF3na=OKnH
`oOoRu
`4a=ar_NoeeHo~e2Seep*=ip”ao®r=o®=DyawofKlolBoo°|eS=KoROOto‘ofpxohKawr
`
`Tyat
`a)2MEeeerHeeassoiy—eHHORKCspease
`0
`.0Rea_
`,
`zr!odor
`BYeTo2fos~
`=_
`NloBKi4|seh,pegetatyeaRPawRmo%%zoWEmea-
`
`
`pisscecbibeseer:+heeXTRSowDEREOS yxcreteEPtEze!3BBSK28=bd42gieaseio|Oo7aeetebeehoB®reas23PwoeEeghate
`
`eecuepedfePeheeoeteeeSF4BERSphehane
`OfosrgeegS*EenetsinyxPye010aeEoBePeeyHeHK4coheeceedes88,Heteyeejoegigteies
`
`oNAlaTEREEESeGeePYBfae%LPFpo
`“xff
`=8peaBERROxqmaK1K%xoth=ZONevBBoabayyoBoPoOheoan“HWEoeietehesolyyMeTSaiywiPy8eensey
`
`_5esetgeitgee©wxpowesneewwohgheetads
`rR-anay~yjOKNo
`meae
`oNso|wi©
`_oo
`©=Snwk©,aaeeOH@ir®OBRa
`
`xot=
`>
`ayy
`‘
`~~
`NXKk
`eal
`a
`ed
`-.Oear
`!
`al
`=xFl
`5
`=
`To
`Hi5smsaiyttcaieegeno7g"Pereghtoce
`~0DcS=ippisgtter(271yrsKoSdrerefuesee
`Zo!@tyiRK
`x
`=reiowee
`rarx
`pHdoaKAicerirteteewesobdbmkCueaeobe
`_ihOFionMmpeaaeezo|B®do7”gvado=2WHdooneyadNitoit
`oe%oloaxqhnfoFoyFBoblMoToboaK==MeRerya
`a~my°2weEBegowo
`KgysO1Oeq
`°~
`Riajo=INtlcient"
`ana
`“x=fyzbee=
`ar5OeeeeTeeKFaoseeeeE®WoSF
`oeY
`'au
`;5
`UFiD
`!
`qn=4:
`A
`Toejo&fdPhezrDWRPNP
`me
`an®>eo®-
`my4
`mBNSopFSBaw<?,y=2a1035Syi22%IFNeKaof&
`Oo—2L>
`oeoe
`1Tom
`07_-
`te
`x
`aohSRSPEE:DesKgie
`x
`—
`apBoBia®iil
`aKSar=o¢
`Koo
`xpeeonRu=Ut
`nga
`-@"ae8BEEREESMeg8a8a
`=XizeA4OoOnaw=yo
`ToKEq
`‘oFod™tkK4eS°ArN14iOaXali=ohBeBeayXF
`Zoer5th=ohld
`wRr+olMez2aak
`Fr7aeehPo=
`oo*PUREROEs
`KxtshywuxBaeeeeOoaSra©=&wrnk2Io<NdFe™‘orByHoat~=alrf
`gyOF*yoRRS
`arloray)“4
`
`i=UkasFhex2=on®=
`aawpigrtetis:ohhoe‘|2SPaafeaayKPaAwwe
`FeEbibeeeeeesOTFiEDy®ooBE©KoheNYoR
`aixX®133%XTOxjo&62S4ayoSDo
`D
`|
`>>
`za
`ee
`2!~
`1
`J
`=~=OT
`>)
`a"
`,
`BpeeToyeoe~©ofa-ebom©©eae
`
`Joot‘artHwtaqn4a7os-
`onn_OF|tpohohOe
`m~
`2-
`=OK
`f
`|
`sorot
`‘Oo—
`yy
`LeeStySepics2adaFEFgyOTxe
`Rrw
`SoEFay8=awoOK
`yORA
`
`eMpoBSTyKoVeeeex
`
`WH=ooLo®araoorah”rl
`NMRuOKavOKAe5>xPyww%TT
`
`otOdMegqRe»ree®rt
`OBymDeda
`Teeweve
`=uSwymh
`
`10-2012-0115535
`
`a
`
`=7
`
`2Oo
`
`Jn
`
`ae
`
`iprma
`
`
`
`
`
`
`
`
`
`mwooh
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`[0625]
`
`{0026}
`
`7i
`
`]
`
`[002
`
`[0028]
`
`[0629]
`
`(0030)
`
`1i
`
`]
`
`[003
`
`
`

`

`SIS 10-2012-0115535
`
`ag] Ste4A - Ve Sele.Se Raza SES He 2YSS HA BSS] US SAS oc] B4
`ALSS ASHE ASE Bo] Jao gaseo] Be. we Sasow, 2 UBS] S42 Vs as B
`AGRoS, PSE SS] UMNEY DW eeege 7G, AAS AS-7N +e SAW eSe BPS
`WE-e] VSS ASE Boley.
`o] Sz UMASS ASAIN AZ BABYS SSI BS SS 714)
`mH, 2 wes] dese 8s ets] SS SPINA, Cee Ss (ourturing) R 4)47 SAS Alespat, AE
`eer, ap Bass] 2EWas 82414 + ao. B Uys] 42 4s, Hye] SS, FA, Aas
`AS, FP pe, AAA, 7], Bee He Zep Ae e424, Geta ye, Sol, &, Bes], Bes] B WS
`
`
`aaa ype] WA, 2 wee] aS A sal 4] 2 SE “HA2] SPAS Mal 4st etget BS Be] x4
`Ee Aeste Aoltt
`
`
`
`
`
`
`
`
`
`e) efoa, Mea YA Me 4 He SAP 2 Fol Aa BY Beliollicle unit,
`Be WAS]
`FUS] Ae] Ja MW ojo] ASS BPy7] al clad + seh.
`
`Bugs He APE AD sd HE | olds] Ys elas] Bo] sls KH,
`
`clo] HasVe 4
`
`BH SY AI UTSPE AMD | ek Bs] Ys ela(ucr), AIAM Vs aaKcK), AAW
`o~
`Ast eaAt
`(PDGF), Bast gelsHep (TGr-Aeb), Sek BA elak SabCTNF-Vsh), BA Uz as elt
`(VEGF), 417 3 lAtONGH), glee2d ACG), AaB Bs ls2ceGr-2), 4g FGFCGE
`acidic), F487 AAAS-ZS zS] ol4t
`(Granulocyte Macrophage-Colony stimulating factor, GM-CSF), >}
`ay-aet zs QlAHG-CSF), SIEEXZICIL-s,
`IL-1, 1L1-? 3,
`IL-6,
`IL-8,
`[L-10), ©Zl, EBA BEF 4,
`2a Ga a(RMP). o]9+ 22 Ase] sje} Aa 4 214b(plant-produced growth factor)= 2 Bese] uy
`ze, Gee Cinflicted) 24, BAA 2A A Vs}rse 42a 2] 4]7-e BSH 44 B42] BA/aAPqA oO] Ba
`- ach. AAs) 34 elAb(selection of growth factors)7} B#-o]43 2e SSA, JS Su, 44g 2
`Ye U2] ASS S41 7151, 4 F A bes MGA] AMAl7) Hal ASWSs AA elt
`3 7a Bel Sa 82471= Al Sle, Bale] 4] Sex vivo treatment)S al ol BS - Wey.
`
`o
`BEA We 4 BS ez} 22 ABS Be dss 2 Dee] o] BES Ha] views Wa else] ajolaz,
`eZee 4-= BAIA BY hair follicle)?] ASS] SA BWACrefractive) BAIS Ysa, BY AGS
`
`Ede zoe Sao. BH Bet BY 836 AS3SV1715 4 res] BHT eS] ATS sel, 3s
`UA] Qe FS]
`RB BS 2B YAKS As 24S (hypoallergenic formula) 2] erH@ 42-7
`
`dq] elzt 24 clas A) BS7] MA 29S 2 Sas Asser}. 12] SS 7/AeBye zee] 2
`
`Belo]Fao Sa] SSAS|4) Be Aes Ut As UzAS SE + VE AZ Os] Bs SBA 4
`st a Alo|ch.
`
`
`
`
`Bees BS tHe ed Ae thes} 2S st oles] AHS-re Ad 4 2 aefeurs SSB
`
`Se 2YES ASHE Aolce. Ast ass aseFetts) Ws] Abel GAs Bape Ba WA xo] Ws
`Saal 84 SoS FAS + UIA, AM DPSS Ads )7T, AM GSS S9s1714, Ase] 4
`we] AVS AY], Bo] B7] Bs, 24 As, 2 AGI BHP 282] 80S 42a, ASS We
`
`a H
`
`
`e oe sal”, # Baer ehass asa Sol 8A U4AS Boe BAAS HS Sees ACE VAS
`Sse, Te WS ASS Aste GAS Asc. AST OS As Whe Hesse, SB Balls
`
`aA, slo] SAS 2 Meeehe Agr. wbe4cAe, SANS AS SSE He Ft
`SSEolty. aee Ad Usthe BY-eze|/MSs}s AYES] ASS Ha Se] 7-Bstr+
`
`
`
`o
`
`Oo
`
`7
`
`LT
`
`oO
`
`
`
`ALA, APSR, "Alt-A (plant-derived)" 94 @l4he SAae AS He Gas AES] 4S oe
`Sa AS else] Bo]
`"A S-A] 4 (plant-produced)"2+ SMA OM ARSC. BpepAl, Bo] "Ae
`ud
`4 2144Cplant-derived growth factor)"= @ SoA VUAaO, AA ¥)3)S (production vehiclo)=
`}
`3°
`jee oF Azo Ha Ade] ob (nonnative), 1S WI US Sra. EH Bol we as els}
`
`J°
`
`-10-
`
`
`
`[0032]
`
`[0633]
`
`{0634}
`
`[0037]
`
`[0038]
`
`{0039}
`
`

`

`SIS 10-2012-0115535
`
`wohTArie
`
`Zz(30ON2x
`
`;
`
`>
`FAAS Be Jee] 4+eee, Besse AZT Zee lsat] EaAl eet Ys ele
`
`Zk(non-human) 24 edad == seh. Mele As leksSe YS FE ASS TA *YTMA—tu
`At [o
`
`ee - Art.
`
`
`AS Sa wash EUs PSA Zle VHS EB BH] Sohe Fle wokAl 2 Seal Arh. HAAS
`2 8aasse + UE ASA 2d BS] HS DNA VSS SBS, OS DNA NSO] EMD, BAA, ec
`AGO 27 S]at, Fe ze Aol ASS + ge Ael ASolrp. +A B4H(genectic manipulation) ®
`aaas WyYS YS SH, bialaphos SE bastaS KES ae] UA, HE WS SH, Ba=zrfe]Al d4
`a 22 844] ide A UAE sche Be ASe Aes] Me oS =] Ar}
`ft
`oy,AGES, Sq +42) EUS At AAS WH] AM. 9 "SAas
`by rero
`(transformat ion)” ee "214 BazS(genetic transformation)"2= 474°2 Ale +4 (inheritance)
`mK
`
`roo4 iy
`
`aH
`
`,
`
`= NAQe, AA S49] Ss WAS) AS WSs] ASS Bae}. SGA2adey Bt GUS Zee Sst
`Nae "@aals(transgenic)" AAS 2aac. # Bee) "gars AS |SAMC transgenic plant
`
`
`
`S32 Fer. AZ Badss| ye] = ofaeebele] 2-7]|6S aBC Agrobacterium-mediated
`
`host cell)" Ale Wo] erayaee oe Sty ole] Sle Att 4, BASSAS 272] Sle att 24
`transformaton (De Blaere et al. 1987) Boast G=(particle-bombardment) HE "+-41%} #(gene gun)" @
`
`{0642}
`
`100434
`
`{0044}
`
`[0045]
`
`0046]
`
`0047}
`
`[0048]
`
`{0049}
`
`AAS: 7) (Klein et al.
`
`(1987); U.S. Pat. No. 4,945,050) 2 3 @Str}.
`
`WO 2006/0163812 @22lsto] AGS, So] HBS He SSS Zsa Aas Gadget YRS WalseAl 7]
`AY SEC},
`
`WO 2005/021762% UALS S¢]s4] QISS FMF GAAS AGE Aol sl] DBAS WF PBS
`HAL Ste}.
`
`2 Eo] we} 4es-7] ASAT SSS AG W4he S71S Vee $F Teeyey Ads + ger
`
`ojo] BQs7) Ser: BAAS Qsel4-b CLE MEV CIGF MEF 1, TGR WE} 2, TGF WEF SS
`
`tee TGF-HE}), BAAS WAelz-a( HE Yap) CTGF-a TEE TGF Ssh), TNR Sa, HB BA clAe(RGF), SA
`BF ay 44} 691 “1(PDGF AA,
`PDGF BB,
`PDGF Rb), “+a A]x% 24 914) CKGF), See 44 4 a 2
`
`bCaFGF @& bFGF), FGF-4, FGF-6, Zh 44 elAbCHGF), SV Us 24 cl 4t(vascular epithelial growth
`factor, VEGF) Wael BlEpo), Mey-F4A 84 SIA-1UGF-1), Meet 44 O14E TI CIGEF-ID),
`IL-1 gs} @ IL-1 Wes SBS, ez“ACL1), Clej|-#71-2 (IL-2), Sle)z1-4(1L-4), ele)21-5CIL-
`5), Qle-#21-6C1L-6), ehA-#21-7 CUIL-7), elA-#41-8C1L-8), AF 21-10CIL-10), A421 13(1L-13), 24
`Z1-15(C1L-15), Sle) Z1-18C11-18), ele) 71-2001L.-20), Bel, BF BAb Olzal TNF-a), BOF DAR 212
`bCTNF-b), GlE,S)S-g(INF-g), AF Bet aS P1AGCSFs), MHA HAAM 4S ZS O1AEGN-CSF),
`OF
`AAS Bet AR CLARG-CSF), EWR 424 S1AKCPLGF), 414 7d4 SIZK(NGF), 21, SS Ga cpyp-4), w
`E]ALAT HEF 4.
`
`
`
`
`2 2gs] Sat sada, IAs ASIA Asse S4 Selqelse Sejfelco) wae ee Ce
`wo eS t+ Boo] ZS= WAallinity
`t
`pt
`aS BV}. a9 Ze qe ws ng Aa, Se] saua-aa,
`
`GST, CBM Se 0) Wels) AaeS aash le Jeb FSS BADE HE VASE FS Wet.
`
`
`SUSBU2 HS BISEs @ BISsyoeeE AAA,
`o] 92 Boop 2 wyq, Seo]
`
`. ISS US Ad Za, Js] wa, Was BA Aaa) We] BEM, Seley, v-eslol=s Gea}
`
`= AANA, ARS Be] WA be] /a4p aS 24) 2 (skin care/dermatological composition)\® 4,28 4
`Ss ws} 42(therapeutic dermatological application) S ASN Be/eISs 29S FP 4B Bye BE
`BTSs Hq SS + Ve SYSS BSTC.
`
`Wyo] ue A RIS FHS Mal, Ys lap] HPL opaapye aYss] 2A s 0.01 ul) 100
`2) 90], WU} EASA AS 0,1 Ul] 50 we] WCEP, TH ws} EE Pe(loss of hair)
`JES YU BA VS AVBS ose aYHS] TA Ss 0,2 U4 50 we] BY SAS MMM.
`
`-11-
`
`

`

`10-20 12-01155385
`
`a
`
`==
`
`aoS
`
`DH
`
`
`
`1
`
`ayA
`
`(skin redness),
`
`*+ (pathology) °]t+
`
`oO
`He
`
`Sxpo] wpe} cheep.
`
`
`ue} 19)
`ae}
`°]aL, Yh
`oO
`Ala
`—_
`&
`1 U4) 400
`| Be,
`
`rl
`
`a0 2-2)
`
`cam
`AL
`
` a3
`
`30a
`
`2] 49) }c},
`
`2
`
`wl
`
`o|
`
`oO
`roy
`aa]
`F
`|
`FAAS
`3]
`1 fee
`Heh.
`39) Daa sl
`
`9] EN
`
`LeT
`
`AAs
`a
`alrlal
`aa
`B]-6}
`
`Ee] Al
`
`*
`di(mimetics), He
`
`Aa] Ale S|
`
`BE AAS
`
`22
`
`Oo)AA
`
`xD
`
`ipne
`
`off!
`
`
`
`oO
`ay ol-BSI
`
`al
`
`==
`
`fO0S0]
`
`[0051]
`
`0052]
`
`[0053]
`
`[0054]
`
`royas
`His le opel a
`qe
`AAT}.
`al]
`SH, Remington's Pharmaceutical Sciences, Gennaro, A. R., ed., 20th edition, 2000: Williams and
`
`USAS
`Wilkins PA,
`BEA.
`
`a4 Ane
`
`25 (paste), AWA(serum), Gat, AE (salve),
`ze
`oe]
`uw
`eet
`Al Al Liposomal preparation), 4,
`=°
`»
`eo]
`°}-B-2
`HO] 7E (paste)
`os
`% ey =
`oO
`
`se] 32
`oO
`vt
`Tre
`ay
`2:3 eo] 3}
`SSE
`Al all
`XE yy] 2-31}
`TBS,
`o] aks} ete,
`2
`YBSo
`
` ARH
`’BA
`42),
`
`<A73% (thickened compositio
`rqBe
`wwxlo
`a,
`HJOAE,
`
`2
`
`="=
`
` o
`
`]
`
`H,
`
`a4
`
`(drop), #41,
`
`= o
`
`il
`
`?
`
`Aa
`
`aj4l(dressing), #F2, Bazl(tincture), Al
`ons
`ol
`OF
`on %
`d] Hote Ub
`3H
`dl(semiliquid) ll,
`}(patch),
`=]
`x5
`HWA
`ll~T
`aT
`
`ae
`‘URE (pomade)
`, W/O Se O/W NEA,
`
`1
`
`ne,
`,
`=F
`
` Z
`
`Glral
`F,
`
`e
`
`Hi
`ty
`
`Lz
`
`43
`
`“iaio
`
`ou
`
`a) a
`
`oO
`ba
`
`«a
`
`e
`
`abe] uy7e 1:1 UA) 1:2¢7
`
`
`$a
`Chydroalcoholic) #°,
`
` Te wWT
`Te
`i
`i
`
`TL
`jadsads
`ytd (sterility), pH,
`fyZezagd aves} 2e Sug,
`
`a
`3
`
`Key
`H el
`
`Cy.
`
`y]
`
`Xx
`~T
`ja], Zale,
`
`3
`|
`
`(NaH2P02/H20--Na2HPO./ 2H20) of]
`AAQo
`a
`
`°a
`
`Le
`3}©,
`os
`O
`iiea
`a“|
`ao
`7A
`[0056]
`— 1] AS]
`i}
`Zl
`stl
`BA ARS
`H]|-%
`All
`tT
`ch
`5Pya
`1Soa
`daa
`TO
`tet
`/
`AlCirritant)= 2}2
`ogee) alale) ch,
`Sy =27) 4-2] (allergenic)
`
`=o
`
`2
`
`
`
`rk
`
`Su
`
`
`
`[0637]
`
`joWDmeRRaD
`
`Le
`cL
`
`AQ) az
`
`cL
`bres aj ae
`
`Tae al At
`O°
`
`FASO! D, wey, a
`
`3}
`
`-12-
`
`=+H
`gee BA
`
`Agel
`
`a|
`
`ae
`
`AALS,
`zlTH
`a] al] oH]
`7Eet,
`
`oOM4
`
`|,nl
`
`rooss}
`
`2-H
`
`EL ol
`“hy
`
`«
`x
`=
`
`, W/O Gwater/oil) HE O/Woil/water) WAALS 2H
`
`
`a °
`
`ol]
`
`=
`
`°.
`Sf] aL,
`8 7hAl
`
`mM7.
`
`abe all,
`
`ss=e
`
`cz
`
`elaby}ete)
`
`
`,Paee&s, HYUS, e418,
`
`

`

`(0058)
`
`{0059}
`
`{0060}
`
`0061]
`
`[0062]
`
`(0063)
`
`[00644
`
`{G065]
`
`[0067]
`
`0068}
`
`SIFSA 10-2012-0115535
`
`
`
`
`
`
`
`
`He, @ Wes] 2YB2 9G SE Hess} CE S54 Usotonic agent), teal, Aeaeol=e], B4ts}
`al, B=telelebz]s} 22 HAA A7yaS =
`
`
`At, Zaad, Sold gese seyuey
`18
`2, SUDssAdoe, lazeg dag, PF sesrAcielleles atl Jal ae] Bas
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ha SBS ASE 71 Wile DBE cy} asso} Ge Sesh), Gea
`a4tshal, aebelelotal, Saal, te4balo]et.
`
`Alals 2 SAA 7A alae” ANA oe ese SI49 AES, HS SUH, 2a, AH, FH, A
`
`Wagal, Heal, S4ial, tetsh, A= ebastal, AZaoeal, tea], Leal, SS (perfume), AS,
`417}
`elvt&(lower
`alkanol) S& Co] BPH + YR Acz ole.
`
`Ge EE AA SES BS ZASG-VS +4 S(delayed-release composition)?] #788 -— ga, S$qetqel=
`B
`Sz (MESA SAOE, Sey AWMSste, WHEASSZLA, FABRA WS-BMSHLA4 SE F744 Ree
`We] Soke 7lairoholA] S214 Zit} BAS SS — Veh. 4S 4, S002 KE Wo Araya
`=e]Ho] 7) eke WS} O]AlS (subcutaneous implant) 4/82]
`2)a-YSs 2YSE Hee | Wry,
`
`34 Bae wesAsAe SAAS, eps, ergs Soe BSH, HAA S2AYSE Tes B43
`ade Ad a4e ctashivl= BAS Mester}, as} Se ease 27 USWE= age] 24s AA
`
`spat, clo] Sa] SY Bae] SHS BAe. Seu, Sy Bae] Sas Dea SazBs| Was S2la al
`Hret7] Ha
`eta shale] ee] Alsstal 4 as)olor ste}, as} Se BAS] Je AAzaiel, A2Geyl, HE
`Rela Bae] BF EPE]-2 0] cf
`
`22} B-Ga4 d= ode ea grass ods 22 4H 2 eds 2B 2 teed Se Fe Aq
`FI, AAA, 2 attads ge Bsa; Apjoles: 2 SA} Se zee AS Asis, zuylo+#
`
`Sa, ted dae, 2 Wades G2 ga) 2 YAZES YAARCE, VAZES SHAE R
`He Axo doles 22 qAaqs=s MSc}. AHABale] F241, 2B 2e]+e+o] E(sodium stearite),
`AUS ABSAE, SYSJad Aeadqd=e SZSAAWoE, AUS Noose SHEeAlES Ze Soje4y
`
`AWSa]; 2doee raeastey SHete= QZ AUVoeHERQISU Ss SHzolese AS Mol e24a 7
`
`mada gdopyedeeed4 qeezseroe 84 2 Ws ge te ADsa4sa 2 sea Be
`
`2HovqyoE, ASN VAP E, -HBOA ZN YAMS, SBSH ges Wr Azxforeele,
`
`
`SyqSaAqad fad=, 4a eye Be-Fodole, 4SAe 22584 BEB yale,
`2qS78a say 444 Did eso ys, Ses 2H2ad eys(4s SH, 3 "Pluronic" 4
`
`
`Base £4), SqSred AAe 2d, 2 SyS18d Fede SF act. seas qe sa
`ad,1,3-384 eae, ¥ SHE edge Bsa Aq esses] de WS 2 AHEMYSE BPS
`
`Wy; SAgqe) dt 282, JES) 2Zeg ASeoOA JES) ZBZ ye ASeor, Soda syzee2
`A0@ FSBSA8 HSH2928 SGsa; ssl 4 SSS FESAeFa, FHS PESOS,
`
`228 @2uyeoE, AJEBSt 2 Ws22 SSF; Ades qe Gade M4 4c] E(disodium
`
`

`

`
`
`
`edetate) 2 AV)=SS4) YRASSES Vespa; MEA] Ye NESA, AS JEGeE, BA, Bal,
`
`
`QB oATe Jesd ZAMES See; PBEM] FE AM Bessa MZE, IG Bel
`
`AMAMYE, YISSoEA, MAd 2 MALS MM}.
`©] SASL or) selol Bspepy, gs
`qe so] FA Qe] HS SAB Gaa = Ae Ae UAB gol}
`
`SIS 10-2012-0115535
`
`
`
`
`
`
`E12 HFS BUse Gade Ae See1a + We] Gal ae Bole
`
`2s VFS Bees Saas Ae seo Ja F Ae] Saal AS mol ecp
`
`32 1GF-1a See Gade Ae Feel Je > Ne] Aaa AS pos
`
`m 46 [L-lae ¥@she Gadd AS pez et TF te] AA Be Mojert
`I
`on |e 2
`
`= ay
`
`ey sy ot, ri, off hits ny iN Ié ax iN wDax se, ro ot o%, 4t
`
`
`Sk(stability challenge) HHAEBS Bolu}.
`
`= 62 ava 7A]
`
`ed Bs} 22, SUV) ae 24E2 F494 A (a) ASA +H (cb) AS FAwinter
`
`Tm
`
`72 "AS BWiwinter feet)"(AS <
`
`a us} Ge, Buys] Fa 27ee2
`
`
`
`(a)
`
`B@ (be B2lal 8A 4
`
`,
`
`(co) @ (= 7 Se) We] A
`
`(xoff
`
`HS =gel Betryelst Aleksl Bete ej] S]et AAAs) BAS HA Cskin deformation) +44
`
`a
`m= 9: Geeta (split-face) GTPaAl, essai oS AS-i EGF ala] B 4l-EGF Wzres Azle
`Wy AA Se) ya Sa Ax. aslo 98 Aeste}.
`
`re ca
`
`rN ca te rr Ze, 18 & 0, oh, Hyby x tl cit nero Hebo
`= 10: AS--7-a] o) EGF (pd-EGH)S Hse] AAS AS
`
`Be] AeA eds Bags Sa@obhe 4-84 BS DAS) As.
`
` WA] EOF)S ree
`
`Jj g4ands AS Sees ASA. AEs Bel pol pe aed qd al
`yA
`EE
`
`BS MEI
`
`
`
`aku
`
`HH, WimilldAd, a4 els EGFS F4-Sh vgaaas HT oe AA 32S}
`(50 mM WAH ph 7.02 Arico. ayesoe Eyvgets aceby 60%: Set
`
`Al
`Hn
`
`DLEFA] Wc},
`‘84 Centrifuge (Heraeus Primo R)o]A] 8300 rpm (|e 15% Sek MABeso, as aq
`SEES Besa, gSeAsS WARS vpo]Sol] AA He (decantAA. FeES| BSI lst SES SDS-
`PAGE & EGF S°]4 @-Jo] 233 AAG BSeo] Sal BAA. co] ASM, EGF He SSE aaa F
`ae] oF 0.019R T+. Ax7} & lel] GAs srt.
`
`EIA Aa 724 GHAs Se Ae] arts B= (Coomassie Blue) 4 FHS HAZ. DE 4a
`
`—_—veL
`44 yAze BSS w
`AQ AG $B HS 24 cls EGS] BAS BYGE, SUG $Se2] & EGF BA]
`
`BPE] SsbA Clow
`yer. el: 1: 27) A, 2: BSAA He SA} FSH,
`3:
`IMAC Bal BA
`through), 4:
`IMAC capture GA)=425) 2] EGF2] Sz].
`
`
`
`{0069}
`
`[0070]
`
`[0071]
`
`{0072}
`
`10073}
`
`[0074]
`
`ALa
`
`Ss
`um
`=.
`{ye
`wity in
`i
`
`
`Jag AS
`Alo] 2: Pewee Aas, aa sls} VEGF B Hele ghet
`AS
`=
`
`N
`] #220] VEGFS BAA Ce AMGeE
`lo] ute} ale] VEGF @-- 244s Be B24 FSEBS 4b
`ALA|q)
`’
`i
`"
`cf
`IMAC SEY}Boqs 7271S 87)3she Ae] aa 4 Aes}
`FEEI S219] SHB50 mM el4t
`
`3 S
`
`0.5 M NaCl, 50 mM °]P]U}=; pH 7.0 SA] +44) 60%
`oOa
`ot MalHAWs: Aol Sa AIBZHeEy Hesgey. Aa aK
`
`2A (50 mM e4has, 0.5 M NaCl, 500 mM FICS; pH 7.0) MAE7] a, Ae
`
`-14-
`
`oh
`DRA] AL}.
`IMAC =A“) =
`AAL tel (decant) A171 al,
`(50 mM clArzS, 0.5 M NaCl, 50 mM oJ F)CHS; pH 7.0) MASA Z TZ, 2AM oelz|a, Aa aes
`A AaAsaac. ASS 335) Bestac}. VEGFS ZBHe SeAzl7] Ha TIS ol WUdSe FE
`A,
`
`5000xgel] A] 15
`
`PAE Aly ,0,4}obtloNNX,&+t12olf
`
`

`

` Healthcare) S WHESBAH °o]26+,
`
`Sa AAA. 4244o8
`LE] Al 7Spal Steel BSh(buffer exchange) S Wa] A Ys ABrpeuAySs
`Sa DAA Was SDS-PAGE B@ AAA SHOE HASTA}.
`°o] 4-9-, VEGF EWS Bees] of 259=
`
`SIS 10-2012-0115535
`
`AAC}, Asp7} KE Qo] Halse}.
`
`
`2 PRAOs Qa, AY Vs Wt VCP BWSUS MWe BIAS AS FSH. A) FSS
`
`SAE Aa] GYAS MAMA, Huy] BS AAs SDS-PAGE A. B) BRACH Aa, Jesus SPE
`He G24 SSE S VEGF) “ays DASE YAH SS. Wel HS 4A:
`
`
`1 37) BS, 2 SH, 3 IMAC SE
`
`s-8 (flowthrough), 4 IMAC Sz] See ofo[art AA aA] sla] Sela, PusAocs Ady #22 4
`c]s|=e VEGF) Ga ep ary.
`
`
`(4, fz aus of xath “iit
`4ce
`Aaeo T]
`(50 mM QIARzEe
`pH 7.0 200 mM NaCl) Se] BBA] A
`MAC <4)]¢o] AQAl7laL, BeAl714, a °]o 8226
`29,71
`Se
`Ho
`mage. 2%, PRAoR gale
`(GE
`PS
`SP-Sepharose
`ABaMEAAS] +=) 44
`IGF-18 BY4ACe AQse 4224 sel ol 2 ws
`ATbe}= Zo] ela a Ale] Ur}, ACE HAS SDS-PAGE B 2S A4(silverstaining)
`&
`Bw So)4 4 IGF-1 @
`Alo] Sls Baa BRee BAM. 27) PEACE Ada AS +eee] 1GF-1 3S
`& GOGAT.
`
`I Te
`S]al PBEM ge
`1GF-1 @ He B2e@BAaS FSSE, SP-Sephasore IECHALE
`
`
`
`ea
`
`
`
`
`
`24 alsl SDS-PAGE 2. el
`
`3 SP-Sepharose IEC#4E2]
`5 My dae: Bbele]otel
`
`
`
`Al Al) edAtel aie ae TS Fo], o]- Wsane SepharoseFre) ABSA°°
`
`
`
`
`
`aja]
`
`1: ee shai] (271 BAL, aie)
`
`6 7) 9°] pH WAH MSS, ogayeS aaa | Mey.
`
`ALB
`
`Sbek( uk 7|S %
`
`EGFC SY AAs AS a)
`
`se] A=
`
`Saas
`
`0.00025
`
`10-90 %
`
`0,1 mM-200 mM
`
`-15-
`
`
`
`& Saas AS $Seze}ye IL-1 Sys] a4] 2 Gel. A) FeeBaste
`AAl ANAS BAS, =F
`us| B= S2isl SDS-PAGE 4. B)
`IL-1 2s} SH HSES] AAR SHE. el 4
`SAA:
`1 8 9 =) Hy), 2
`5% NaCl @2]2,
`7 75% NaCl
`
`EE, 3 IMAC Sr, 14
`
`IMAC BAH,
`
`5 SA mac Sze, 6 ECS] 3
`
`SU, 8 100 % NaCl @CH. D: FSH, IL-la: MeyFz71 1 Sy}.
`
`
`
`[0075]
`
`[0077]
`
`{0673}
`
`[0079]
`
`fOO80}
`
`O08 14
`
`[0082]
`
`[0083]
`
`[0084]
`
`[0085]
`
`[0086]
`
`[0087]
`
`[0088]
`
`[0089]
`
`

`

`ron90}
`
`f0G94]
`
`ron92}
`
`£0093]
`
`(0094)
`
`£0095]
`
`{0096]
`
`£0097]
`
`{0098}
`
`£0099]
`
`{0100}
`
`(0101)
`
`{0102]
`
`[0103]
`
`[0104]
`
`f0105]
`
`{0106]
`
`[0107]
`
`[0108]
`
`0109]
`
`fO110]
`
`fOlLd]
`
`fO112]
`
`(0113]
`
`LOL 14]
`
`[Ol 1S]
`
`[OL 16]
`
`fO117]
`
`fOL is]
`
`fol 194
`
`[0120]
`
`fo12i
`
`[0122
`
`[0123]
`
`Yall
`
`Se epee] E
`
`oS
`
`Suet WCq.s)
`
`0, 01-2
`
`0, 1-10
`
`SIS 10-201